Seminars in Oncology
Volume 33, Issue 2 , Pages 240-249, April 2006

Infectious Complications of Chronic Lymphocytic Leukemia

  • Punit D. Wadhwa

      Affiliations

    • Section of Hematology/Oncology, Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN
    • Corresponding Author InformationAddress correspondence to Punit D. Wadhwa, MD, Section of Hematology/Oncology, 111 E, Veterans Affairs Medical Center, One Veterans Dr, Minneapolis, MN 55417
  • ,
  • Vicki A. Morrison

      Affiliations

    • Section of Hematology/Oncology, Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN
    • Section of Infectious Disease, Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN

Infectious complications continue to be one of the major causes of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). The pathogenesis of infections in these patients is multifactorial. Hypogammaglobulinemia is an important predisposing factor for infection in patients with early-stage disease and for those treated with conventional alkylating agents. However, the proportion of patients treated with purine analogs and monoclonal antibodies such as rituximab and alemtuzumab is increasing. As a result of this therapy, these patients often experience profound and sustained T-cell immunodeficiency. Consequently, the spectrum of organisms causing infections in these patients is changing from common bacterial organisms to less common opportunistic pathogens such as Pneumocystis, Listeria, mycobacteria, herpesviruses, and Candida. This review focuses on the pathogenesis and risk factors for infections in patients with CLL, the spectrum of infectious organisms associated with the newer agents, and the management of these infections with an emphasis on prophylaxis and vaccination strategies.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(05)00507-5

doi:10.1053/j.seminoncol.2005.12.013

Seminars in Oncology
Volume 33, Issue 2 , Pages 240-249, April 2006